A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Kalaris Therapeutics, Inc.
KLRS
$834K
Mkt Cap
$3.73
-4.85%
Kalaris Therapeutics, Inc. (KLRS) has a 5-year average return on invested capital (ROIC) of -19.2%. This is below average and may indicate limited pricing power.
Kalaris Therapeutics, Inc. (KLRS) has a market capitalization of $85M. It is classified as a small-cap stock.
Kalaris Therapeutics, Inc. (KLRS) does not currently pay a regular dividend.
Kalaris Therapeutics, Inc. (KLRS) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Kalaris Therapeutics, Inc. (KLRS) generated $-20 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Kalaris Therapeutics, Inc. (KLRS) reported earnings per share (EPS) of $-106.61 in its most recent fiscal year.
Kalaris Therapeutics, Inc. (KLRS) has a return on equity (ROE) of 58.1%. This indicates the company generates strong returns for shareholders.
AlloVir, Inc. (“AlloVir”) is a biopharmaceutical company. AlloVir’s initial focus was on developing highly innovative allogeneic T cell therapies to treat and prevent devastating viral diseases. AlloVir’s innovative and proprietary virus-specific T cell (“VST”) therapy platform allows AlloVir to generate off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. This included: (1) posoleucel (ALVR105), an investigational off-the-shelf multi-virus-specific T cell therapy, which targeted six viral pathogens in immunocompromised individuals: adenovirus (“AdV”), BK virus (“BKV”), cytomegalovirus (“CMV”), Epstein-Barr virus (“EBV”), human herpesvirus-6 (“HHV-6”) and JC virus (“JCV”); (2) ALVR106, an allogeneic, off-the-shelf VST therapy candidate developed to target devastating diseases caused by four respiratory viruses: human metapneumovirus (“hMPV”), influenza, parainfluenza virus (“PIV”)
| Segment | 2017 | % of Total |
|---|---|---|
CPRIT | $9M | 100% |
| Metric | TTM | FY2019 |
|---|---|---|
| Revenue | 0 | - |
| Net Income | -43M | -24M |
| EPS | $-4.19 | $-106.61 |
| Free Cash Flow | 0 | -20M |
| ROIC | -30.0% | -19.2% |
| Gross Margin | - | - |
| Debt/Equity | 0.10 | -0.35 |
| Dividends/Share | $0.00 | - |
| Operating Income | -46M | -27M |
| Operating Margin | 0.0% | - |
| ROE | -55.1% | 58.1% |
| Shares Outstanding | 23M | 0M |
| Metric | ||
|---|---|---|
| Income Statement | ||
| Revenue | N/A | 0 |
| Gross Margin | N/A | N/A |
| R&D | 16M | 31M |
| SG&A | 11M | 15M |
| EBIT | -27M | -46M |
| Op. Margin | N/A | 0.0% |
| Net Income | -24M | -43M |
| Net Margin | N/A | 0.0% |
| Non-Recurring | 0 | 0 |
| Returns on Capital | ||
| ROIC | -19.2% | -30.0% |
| ROE | 58.1% | -55.1% |
| ROA | -17.1% | -35.7% |
| Cash Flow | ||
| Op. Cash Flow | -20M | -38M |
| Free Cash Flow | -20M | 0 |
| Owner Earnings | -23M | -40M |
| CapEx | 339K | 0 |
| Maint. CapEx | 19K | 19K |
| Growth CapEx | 320K | 0 |
| D&A | 19K | 19K |
| CapEx/OCF | N/A | 0.0% |
| Capital Allocation | ||
| Dividends Paid | 0 | 0 |
| Dividend Yield | N/A | N/A |
| Share Buybacks | 0 | 0 |
| Buyback Yield | N/A | 0.0% |
| Stock-Based Comp | 2.9M | 1.9M |
| Debt Repayment | 0 | 0 |
| Balance Sheet | ||
| Net Debt | N/A | -110M |
| Cash & Equiv. | 61M | 118M |
| Long-Term Debt | N/A | 7.5M |
| Debt/Equity | -0.35 | 0.10 |
| Interest Coverage | -213.6 | -213.6 |
| Equity | -52M | 79M |
| Total Assets | 139M | 122M |
| Total Liabilities | 18M | 43M |
| Intangibles | N/A | N/A |
| Retained Earnings | -55M | -160M |
| Working Capital | 118M | 109M |
| Current Assets | 127M | 119M |
| Current Liabilities | 9.1M | 9.7M |
| Per Share Data | ||
| EPS | -106.61 | -4.19 |
| Owner EPS | -103.14 | -1.76 |
| Book Value | -230.31 | 3.44 |
| Cash Flow/Share | -90.13 | -1.90 |
| Dividends/Share | N/A | 0.00 |
| Shares Out. | 0.2M | 22.9M |
| Valuation | ||
| P/E Ratio | N/A | -0.9 |
| P/FCF | N/A | N/A |
| EV/EBIT | N/A | N/A |
| Price/Book | N/A | 1.1 |
| Price/Sales | N/A | N/A |
| FCF Yield | N/A | N/A |
| Market Cap | N/A | 85M |
| Avg. Price | N/A | 3.73 |
| Year-End Price | N/A | 3.73 |
Kalaris Therapeutics, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The Ledger Terminal provides 1 years of financial data for Kalaris Therapeutics, Inc. (KLRS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Kalaris Therapeutics, Inc. (KLRS) has a book value per share of $-230.31, based on its most recent annual SEC filing.